Ocular Therapeutix Stock News

Ocular Therapeutix, Inc. (NASDAQ:OCUL) major shareholder Summer Road Llc bought 10,510 shares of the stock in a transaction on Monday, December 13th. The shares were bought at an average cost of $6.50 per share, with a total value of $68,315.00. The acquisition was disclosed in a document filed with the SEC, which is available at []

Ocular Therapeutix, Inc. (NASDAQ:OCUL) major shareholder Summer Road Llc acquired 10,510 shares of the stock in a transaction dated Monday, December 13th. The shares were purchased at an average cost of $6.50 per share, with a total value of $68,315.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which []

Ocular Therapeutix Inc. (NASDAQ:OCUL)s traded shares stood at 0.69 million during the last session, with the companys beta value hitting 1.73. At the close of trading, the stocks price was $6.55, to imply a decrease of -3.96% or -$0.27 in intraday trading. The OCUL shares 52-week high remains $24.30, putting it -270.99% down since that After This Weeks 6.33% Gain In Ocular Therapeutix Inc. (NASDAQ: OCUL), We Just Learned Something New Read More »

Ocular Therapeutix, Inc. (NASDAQ:OCUL) major shareholder Summer Road Llc purchased 5,300 shares of the firms stock in a transaction that occurred on Wednesday, December 8th. The stock was bought at an average price of $6.75 per share, for a total transaction of $35,775.00. The purchase was disclosed in a legal filing with the SEC, which []

According to Market Study Report, Chitosan Based Hydrogel Market provides a comprehensive analysis of the Chitosan Based Hydrogel Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in

Ocular Therapeutix Inc (NASDAQ: OCUL ) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The clinical trial achieved its pre-specified primary endpoint, demonstrating a statistically significant change of bulbar conjunctival Full story available on Benzinga.com

Ocular Therapeutix (NSDQ:OCUL) announced today that it reported positive results from a Phase 2 trial of its dry eye disease treatment. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based Phase 2 clinical trial evaluated OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The randomized, double-masked, vehicle-controlled, multi-center trial evaluated two different formulations of […] The post Ocular Therapeutix touts positive trial results of ophthalmic insert for dry eye disease appeared first on Drug Delivery Business .

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.

In last trading session, Ocular Therapeutix Inc. (NASDAQ:OCUL) saw 0.56 million shares changing hands with its beta currently measuring 1.73. Companys recent per share price level of $6.16 trading at -$0.35 or -5.38% at ring of the bell on the day assigns it a market valuation of $473.40M. That closing price of OCULs stock is The 12-Month Price Target For Ocular Therapeutix Inc. (NASDAQ:OCUL) Is Now $30.00. Read More »

Morgan Stanley boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 47.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 491,867 shares of the biopharmaceutical companys stock after buying an additional 157,541 shares during the period. Morgan Stanley owned approximately 0.64% []

Wall Street analysts expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to announce earnings per share (EPS) of ($0.23) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Ocular Therapeutixs earnings, with estimates ranging from ($0.26) to ($0.21). Ocular Therapeutix also posted earnings of ($0.23) per share in the same quarter last year. []

Ocular Therapeutix (NASDAQ:OCUL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Profitability This table compares Ocular Therapeutix and Corvus Pharmaceuticals net margins, return on equity and []

Akouos (NASDAQ:AKUS) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Akouos and Ocular Therapeutix, []